OPA868-2

OPA868-2 is a proprietary payload-linker candidate developed by Serilink Biotechnology as part of its Seri-OPA™ platform. The Seri-OPA™ technology is designed to optimize the therapeutic index of conjugates by utilizing advanced linker-payload chemistry. OPA868-2 specifically incorporates a Topoisomerase I inhibitor (Top1i) payload, which is typically a camptothecin derivative, designed for high cytotoxic potency and the ability to induce bystander killing effects in the tumor microenvironment. The linker component is engineered for high systemic stability to minimize off-target toxicity while ensuring efficient cleavage and payload release upon internalization into target cells. OPA868-2 is intended for the development of various therapeutic modalities, including antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs), and antibody-radionuclide conjugates (ARCs), primarily for the treatment of solid tumors.

Other names

OPA868-2OPA-868-2OPA 868-2